High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Clinical Cancer Research

• Publication date

  2002-05-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 12006533
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.

  2001cited by this paper
• Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.

  2001cited by this paper
• The possible role and application ofWT1 in Human Leukemia

  2001cited by this paper
• National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000.

  2001cited by this paper
• Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.

  2000cited by this paper
• Detection of a Novel Truncated WT1 Transcript in Human Neoplasia

  2000cited by this paper
• Quantitative analysis of estrogen receptor‐α and ‐β messenger RNA expression in breast carcinoma by real‐time polymerase chain reaction

  2000cited by this paper
• Hypermethylation of the Wilms' tumor suppressor gene CpG island in human breast carcinomas

  1999cited by this paper
• Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells.

  1998cited by this paper
• Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer.

  1997cited by this paper
• Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis.

  1996cited by this paper
• Fifth International Conference on Adjuvant Therapy of Breast Cancer, St Gallen, March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer.

  1995cited by this paper
• International Consensus Panel on the treatment of primary breast cancer. V: Update 1998.

  1995cited by this paper
• Regulation of the proto-oncogenes bcl-2 and c-myc by the Wilms' tumor suppressor gene WT1.

  1995cited by this paper
• Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer.

  1995cited by this paper
• WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.

  1994cited by this paper
• Repression of the transforming growth factor-beta 1 gene by the Wilms' tumor suppressor WT1 gene product.

  1994cited by this paper
• Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product.

  1993cited by this paper
• Human platelet-derived growth factor A chain is transcriptionally repressed by the Wilms tumor suppressor WT1.

  1992cited by this paper
• Intragenic homozygous deletion of the WT1 gene in Wilms' tumor.

  1992cited by this paper
• Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.

  1992cited by this paper
• Zinc finger point mutations within the WT1 gene in Wilms tumor patients.

  1992cited by this paper
• Germline mutations in the Wilms' tumor suppressor gene are associated with abnormal urogenital development in Denys-Drash syndrome.

  1991cited by this paper
• Alternative splicing and genomic structure of the Wilms tumor gene WT1.

  1991cited by this paper
• Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus.

  1990cited by this paper
• Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping

  1990cited by this paper
• Prognostic value of histologic grade nuclear components of Scarff‐Bloom‐Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas

  1989cited by this paper
• Adjuvant Therapy of Primary Breast Cancer

  1989cited by this paper

• Selective arm-usage of pre-miR-1307 dysregulates angiogenesis and affects breast cancer aggressiveness

  2025cites this paper
• WT1 gene: a potential therapeutic target for multiple cancer treatment strategies

  2025cites this paper
• A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence

  2025cites this paper
• Cell membrane vaccine delivery system: A review of the recent advances against breast cancer.

  2025cites this paper
• 5-Hydroxytryptamine promotes non-small cell lung cancer metastasis via the SNRPG/WT1/CDK14 Axis

  2025cites this paper
• Overexpression of WT1 in all molecular subtypes of breast cancer and its impact on survival: exploring oncogenic and tumor suppressor roles of distinct WT1 isoforms

  2024influential citation
• Comparison among Various Prognostic Pathologic Markers Revealed Significantly Poorer Prognosis in Non-basal-like than in Basal-like Triple Negative Breast Cancer

  2024cites this paper
• Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence

  2024cites this paper
• Primary testicular lymphoma demonstrates overexpression of the Wilms tumor 1 gene and different mRNA and miRNA expression profiles compared to nodal diffuse large B‐cell lymphoma

  2023cites this paper
• Cancer Vaccines for Triple-Negative Breast Cancer: A Systematic Review

  2023cites this paper
• The Prognostic Significance of FOXD1 Expression in Head and Neck Squamous Cell Carcinoma

  2023cites this paper
• The prognostic value of p53 and WT1 expression in cancer: new molecular insights and epigenetics explanations lead to a new medical hypothesis

  2023cites this paper
• Epidemiology of Glioblastoma Multiforme–Literature Review

  2022cites this paper
• Biomarker Expression Profiling in Cervix Carcinoma Biopsies Unravels WT1 as a Target of Artesunate

  2022cites this paper
• Clinical significance of the increased expression of the WT1 gene in peripheral blood of patients with acquired aplastic anemia

  2022cites this paper
• WT1 Inhibits Human Renal Carcinoma Cell Proliferation and Induces G2/M Arrest by Upregulating IL-24 Expression

  2022cites this paper
• Strategies for Manipulating T Cells in Cancer Immunotherapy

  2022cites this paper
• T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors

  2021cites this paper
• Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab

  2021cites this paper
• Truncated WT1 Protein Isoform Expression Is Increased in MCF-7 Cells with Long-Term Estrogen Depletion

  2021cites this paper
• Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies

  2021cites this paper
• Novel promising serum biomarkers for canine mammary tumors

  2021cites this paper
• Galinpepimut-S (GPS): an investigational agent for the treatment of acute myeloid leukemia

  2021cites this paper
• Comprehensive analysis based on DNA methylation and RNA-seq reveals hypermethylation of the up-regulated WT1 gene with potential mechanisms in PAM50 subtypes of breast cancer

  2021cites this paper
• Expression Levels of the CA9, WT1, and PRAME Genes and Genotyping-Associated Antigens for the Diagnosis and Prognosis of Colorectal Cancer

  2021cites this paper
• Current Immunotherapeutic Strategies for the Treatment of Glioblastoma

  2021cites this paper
• Efficacy and safety of Wilms’ tumor 1 helper peptide OCV-501 in elderly patients with acute myeloid leukemia: a multicenter, randomized, double-blind, placebo-controlled phase 2 trial

  2021cites this paper
• A G316A Polymorphism in the Ornithine Decarboxylase Gene Promoter Modulates MYCN-Driven Childhood Neuroblastoma

  2021cites this paper
• Clinicopathological significance of WT1 expression in invasive breast carcinoma with >90% mucinous component

  2021cites this paper
• Identi cation and Validation of a Five-gene Signature Associated with Overall Survival in Breast Cancer Patients

  2020cites this paper
• The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism

  2020cites this paper
• Identification and Validation of a Five-Gene Signature Associated With Overall Survival in Breast Cancer Patients

  2020cites this paper
• Diagnostic and Prognostic Role of WT1 Immunohistochemical Expression in Uterine Carcinoma: A Systematic Review and Meta-Analysis across All Endometrial Carcinoma Histotypes

  2020cites this paper
• Regulation of breast cancer metastasis signaling by miRNAs

  2020cites this paper
• Immunotherapy Advances for Epithelial Ovarian Cancer

  2020cites this paper
• GSK3β-Mediated Expression of CUG-Translated WT1 Is Critical for Tumor Progression

  2020cites this paper
• Identification of differentially expressed lncRNAs and mRNAs in luminal-B breast cancer by RNA-sequencing

  2019cites this paper
• Truncated WT1 protein isoform expression is increased in MCF-7 cells in a long-term estrogen depletion

  2019influential citation
• shRNA-WT1 Potentiates Anticancer Effects of Gemcitabine and Cisplatin Against B16F10 Lung Metastases In Vitro and In Vivo

  2019cites this paper
• Investigation of Insulin-Like Growth Factor-1 (IGF-1), P53, and Wilms’ Tumor 1 (WT1) Expression Levels in the Colon Polyp Subtypes in Colon Cancer

  2019cites this paper
• DNA Methylation Readers and Cancer: Mechanistic and Therapeutic Applications

  2019cites this paper
• A double-blind randomized comparative clinical trial to evaluate the safety and efficacy of dendritic cell vaccine loaded with WT1 peptides (TLP0-001) in combination with S-1 in patients with advanced pancreatic cancer refractory to standard chemotherapy

  2019cites this paper
• WT1 Expression as a Potential Biomarker of Malignancy in Canine Breast Tumor

  2019cites this paper
• Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers

  2018cites this paper
• Role of WT1 in Ischaemic Angiogenesis

  2018cites this paper
• Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?

  2018cites this paper
• Myeloid Leukemia Vaccines

  2018cites this paper
• Differential sensitization of two human colon cancer cell lines to the antitumor effects of irinotecan combined with 5-aza-2'-deoxycytidine.

  2018cites this paper
• T Cell Receptor Mimic Antibodies

  2018cites this paper
• SEROPREVALENCE OF HUMAN T-CELL LYMPHOTROPHIC VIRUS AND ITS ASSOCIATION WITH WILMS TUMOUR ANTIGEN AMONG WOMEN ATTENDING POST-NATAL CLINICS IN ZARIA NIGERIA.

  2018cites this paper
• WT1 expression in vessels varies with histopathological grade in tumour-bearing and control tissue from patients with breast cancer

  2018cites this paper
• Développement d’un modèle murin syngénique et immun de leucémie aiguë myéloïde et de maladie résiduelle mesurable surexprimant ou non le gène Wilms Tumor 1

  2018cites this paper
• WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel

  2017cites this paper
• The role of WT1 isoforms in vasculogenic mimicry and metastatic potential of human triple negative breast cancer cells.

  2017cites this paper
• Differential detection of cytoplasmic Wilms tumor 1 expression by immunohistochemistry, western blotting and mRNA quantification.

  2017cites this paper
• Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6

  2017cites this paper
• Simultaneous in vitro generation of CD8 and CD4 T cells specific to three universal tumor associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia

  2017cites this paper
• Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive Stage II/III breast cancer: a randomized Phase I study

  2017cites this paper
• Cancer Biology: Severe Cumulative Delayed Type Hypersensitivity Reactions

  2017cites this paper
• Functional characterisation of tumour-specific T cell responses in pancreatic cancer

  2017cites this paper
• Scalable non-negative matrix tri-factorization

  2017cites this paper
• microRNA-361 targets Wilms' tumor 1 to inhibit the growth, migration and invasion of non-small-cell lung cancer cells.

  2016cites this paper
• WT1 shRNA delivery using transferrin-conjugated PEG liposomes in an in vivo model of melanoma.

  2016cites this paper
• Investigating the differential instructive roles of WT1's isoforms

  2016cites this paper
• Utilization of Wilms’ tumor 1 antigen in a panel for differential diagnosis of ovarian carcinomas

  2016cites this paper
• WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non‐MYCN‐amplified neuroblastoma

  2016cites this paper
• Differential expression of immunohistochemical markers in primary lung and breast cancers enriched for triple‐negative tumours

  2016cites this paper
• Functional Role of WT 1 in Prostate Cancer

  2016cites this paper
• Functional Role of WT1 in Prostate Cancer

  2016cites this paper
• A Zbtb7a proto‐oncogene as a novel target for miR‐125a

  2016cites this paper
• Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide

  2016cites this paper
• Deficiency in WT1-targeting microRNA-125a leads to myeloid malignancies and urogenital abnormalities

  2016cites this paper
• Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies.

  2015cites this paper
• Therapeutic Agents Based on DNA Sequence Specific Binding.

  2015cites this paper
• Wilms' tumor 1 (WT1) expression and prognosis in solid cancer patients: a systematic review and meta-analysis

  2015cites this paper
• Biological activity of Pyrrole-Imidazole polyamides in vivo

  2015influential citation
• Methylome sequencing in triple-negative breast cancer reveals distinct methylation clusters with prognostic value

  2015cites this paper
• Clinicopathological significance and prognostic value of Wilms' tumor gene expression in colorectal cancer

  2015cites this paper
• Wilms’ tumor gene WT1 promotes homologous recombination‐mediated DNA damage repair

  2015cites this paper
• WT1 role in mammary gland and breast cancer biology

  2015influential citation
• The density of microvessels positive for Wilms’ tumour-1 protein (WT-1) is an independent predictor of recurrence risk in meningiomas

  2015cites this paper
• Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population.

  2015cites this paper
• IMPACT OF DIFFERENTIATION STATUS OF KIDNEY PROGENITORS IN WILMS TUMOR DEVELOPMENT

  2015cites this paper
• A genome-wide association study identifies WT1 variant with better response to 5-fluorouracil, pirarubicin and cyclophosphamide neoadjuvant chemotherapy in breast cancer patients

  2015cites this paper
• Adoptive T-cell therapy for Leukemia

  2014cites this paper
• Correlation of Wilms' tumor 1 isoforms with HER2 and ER-α and its oncogenic role in breast cancer.

  2014cites this paper
• WT1 vaccination in acute myeloid leukemia: new methods of implementing adoptive immunotherapy

  2014cites this paper
• The Wilms' Tumor Gene WT1 − 17AA/− KTS Splice Variant Increases Tumorigenic Activity Through Up-Regulation of Vascular Endothelial Growth Factor in an In Vivo Ovarian Cancer Model

  2014cites this paper
• Innovative tools for early detection of cancer

  2014cites this paper
• Wilms' tumor gene (WT1) expression correlates with vascular epithelial growth factor (VEGF) in newly acute leukemia patients undergoing chemotherapy.

  2014cites this paper
• The frequency and significance of WT-1 expression in serous endometrial carcinoma.

  2014cites this paper
• Wt1 regulates the expression of inhibitory chemokines during heart development

  2014cites this paper
• WT1 regulates angiogenesis in Ewing Sarcoma

  2014cites this paper
• High levels of Wilms' tumor 1 (WT1) expression were associated with aggressive clinical features in ovarian cancer.

  2014cites this paper
• Proteomics analysis of siRNA-mediated silencing of Wilms' tumor 1 in the MDA-MB-468 breast cancer cell line.

  2014cites this paper
• Prostate cancer invasion and metastasis: insights from mining genomic data.

  2013cites this paper
• Wilms’ Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

  2013cites this paper
• University of Birmingham Wilms' Tumour 1 (WT1) peptide vaccination in patients with acute myeloid leukaemia induces short-lived WT1-specific immune responses

  2013cites this paper
• Activity of a Py–Im Polyamide Targeted to the Estrogen Response Element

  2013cites this paper
• WT1 protein expression in astrocytic tumors and its relationship with cellular proliferation index

  2013cites this paper